BiondVax Announces Receipt of IRB Ethics ("Helsinki") Committee Approvals for the Initiation of Second Phase II Clinical Trial

BiondVax Announces Receipt of IRB  Ethics ("Helsinki")  Committee Approvals for the Initiation of Second Phase II Clinical Trial for  Universal Influenza Vaccine

Ness Ziona, Israel -  29 August 2011 - BiondVax  Pharmaceuticals Ltd. (TASE:  BNDX), an Israeli biopharmaceutical company at the forefront of global  efforts towards the development of a universal influenza vaccine, today  announced that it has received the approvals of the Ethics ("Helsinki") Committees  of the Institutional Review Boards (IRB) of both the Hadassah Clinical  Research Center at Hadassah University Hospital in Jerusalem ("Hadassah") and  the Tel Aviv Sourasky Medical Center ("Ichilov"), to perform a Phase II  clinical trial to evaluate the safety, immunogenicity and priming potential  of BiondVax's universal influenza vaccine candidate, the Multimeric-001.

The principal investigators conducting the clinical trial will be Prof.  Yoseph Caraco, Director of the Hadassah Clinical Research Center (CRC) and Dr.  Jacob Atsmon, Director of the Ichilov CRC.

The trial is designed to include a total of 120 participants, both  male and female, 65 years of age and older.  Screening of the potential participants  will commence immediately, with the first administrations of the vaccine  expected to take place in October 2011.  The Company expects to be able to  report headline results from this trial by the end of the first quarter of  2012.

Dr.  Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, said, "We are  very pleased to have received the necessary approvals for the initiation of  our second Phase II clinical trial, which follows the successful completion  of our first Phase II trial a few months ago.  We are looking forward to continuing  our progress towards the successful development of the world's first truly  universal influenza vaccine."

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.